James Basta - 01 Mar 2023 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: EVP, General Counsel
Signature: James Basta
Issuer symbol: NTLA
Transactions as of: 01 Mar 2023
Net transactions value: -$47,741
Form type: 4
Filing time: 03 Mar 2023, 16:10:35 UTC
Previous filing: 06 Jan 2023
Next filing: 05 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Award	$0	+24,539	+125%	$0.000000	44,098	01 Mar 2023	Direct	F1
transaction	NTLA	Common Stock	Award	$0	+12,269	+28%	$0.000000	56,367	01 Mar 2023	Direct	F1
transaction	NTLA	Common Stock	Sale	$47,741	-1,088	-1.9%	$43.88	55,279	02 Mar 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NTLA	Stock Option (right to buy)	Award	$0	+34,674		$0.000000	34,674	01 Mar 2023	Common Stock	34,674	$40.75	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2	Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on March 1, 2023.
F3	This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.